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may guide the prioritization of steps to be taken for enhanc-
ing integration of toxicogenomics databases.
Keywords Databases · Data sharing · Hazard 
identification · Human · Omics technologies · Risk 
assessment
Background
Traditional approaches for the assessment of toxicologi-
cal properties of compounds rely heavily on animal testing 
(Chen et al. 2012). Several issues related to animal experi-
ments have led to the need for alternative experimental 
methods. Ethical issues concerning animal welfare have 
resulted in new legislation limiting animal testing, e.g. 
the Directive on Cosmetic Products (European Commis-
sion 2010b). Registration, Evaluation, Authorization and 
restriction of Chemicals (REACH; European Commission 
2007) provides recommendations to limit animal experi-
ments. Furthermore, studies have shown that the results of 
multiple animal models for evaluating chemical safety are 
not reliably applicable to humans and vice versa (Hartung 
2009).
The consequent need for alternatives to animal testing 
has led to the expansion of toxicogenomics, e.g. a subfield 
of toxicology that applies—omics technologies for risk 
assessment, as a part of the broader application of ‘omics’ 
technologies for testing toxicity (Sycheva et al. 2013).
The report ‘Toxicity Testing in the 21th Century: A 
Vision and Strategy’ of the National Research Council 
(NRC) in the USA (National Research Council (NRC) 
2007) states that understanding adverse outcomes of com-
pounds requires a large amount of data, which have to be 
made publicly available. However, to date, existing public 
Abstract A joint US-EU workshop on enhancing data 
sharing and exchange in toxicogenomics was held at the 
National Institute for Environmental Health Sciences. 
Currently, efficient reuse of data is hampered by prob-
lems related to public data availability, data quality, data-
base interoperability (the ability to exchange informa-
tion), standardization and sustainability. At the workshop, 
experts from universities and research institutes presented 
databases, studies, organizations and tools that attempt to 
deal with these problems. Furthermore, a case study show-
ing that combining toxicogenomics data from multiple 
resources leads to more accurate predictions in risk assess-
ment was presented. All participants agreed that there is a 
need for a web portal describing the diverse, heterogene-
ous data resources relevant for toxicogenomics research. 
Furthermore, there was agreement that linking more data 
resources would improve toxicogenomics data analysis. 
To outline a roadmap to enhance interoperability between 
data resources, the participants recommend collecting user 
stories from the toxicogenomics research community on 
barriers in data sharing and exchange currently hampering 
answering to certain research questions. These user stories 
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databases for toxicogenomics and other toxicity data only 
exist to a small extent compared to what is envisioned in 
the report. Here, several issues are of concern:
•	 Many toxicogenomics and other toxicity data have been 
generated, of which large amounts are now stored in 
separate databases (or not at all, for that matter). How-
ever, problems related to public data availability, data 
quality, interoperability (the ability to exchange infor-
mation), standardization and sustainability hamper effi-
cient use of these data.
•	 Reasons for not making data publicly available are 
related to confidentiality, personal privacy and intellec-
tual property (Briggs et al. 2012). Furthermore, not all 
funding agencies and journals require that data are made 
publicly available (Woodall and Goldberg 2008). There 
is a lack of support for data collection and deposition, 
and facilities for local data storage in individual labo-
ratories have to be increased (Waters and Yauk 2007). 
Moreover, data are pre-processed and normalized fol-
lowing a specific protocol from a particular laboratory, 
instead of having standardized pre-processing and nor-
malization workflows (Woodall and Goldberg 2008). 
Furthermore, complex datasets are often fragmented 
across different databases, because databases are often 
limited to only capturing specific data types (Sansone et 
al. 2012).
•	 It has been observed that some datasets in public data-
bases are of low quality due to insufficient data curation 
(Waters and Yauk 2007). Moreover, experimental design 
and protocols are often poorly explained (Benfenati 
et al. 2010; Christensen et al. 2011; Waters and Yauk 
2007). Another common issue is that data are often not 
well organized, so that they can be difficult to find (Berg 
et al. 2011).
•	 In addition, datasets are frequently deposited in separate 
databases in different formats and with different anno-
tations (Sansone et al. 2012), which hampers interoper-
ability between databases. Furthermore, there are insuf-
ficient bioinformatics tools to integrate the various data 
(Berg et al. 2011; Briggs et al. 2012).
•	 Overall, there is a lack of standardization among dif-
ferent databases because each field uses its own agree-
ments (Benfenati et al. 2010; Sansone et al. 2012). Fur-
ther, disparate laboratories have their own experimental 
protocols, preprocessing and normalization procedures 
(Berg et al. 2011), which makes it difficult to compare 
and combine data from different laboratories.
•	 Problems with creating a sustainable data infrastruc-
ture are complicated by the lack of available funding in 
proportion to the increase in amount and complexity of 
data (Christensen et al. 2011; Waters and Yauk 2007). 
Moreover, people are often not aware of the existence of 
current databases and their optimal usage, due to insuf-
ficient communication, dissemination, education and 
training (Berg et al. 2011; Waters and Yauk 2007).
To discuss these and other challenges in toxicogenomics 
data management, a joint EU-US workshop was organized, 
sponsored by Research Data Alliance (RDA) Europe and 
the National Institute of Environmental Health Sciences 
(NIEHS; NC, USA), which focused on the identification 
of opportunities for global integration of toxicogenomics 
databases. Contributions from universities and research 
institutes helped to get insight in current data sharing and 
exchange in toxicogenomics. Gaps and needs were identi-
fied, and opportunities for improvement were discussed. 
This report summarizes the workshop presentations, dis-
cussions and resulting recommendations.
Workshop presentations and discussion
Currently, there are increasing demands on chemical 
risk assessment (Jos Kleinjans, Maastricht University). 
Because of the high failure rate of new drug candidates 
due to unmanageable toxicity, there is a need for improved 
approaches for human risk assessment. Further, the EU 
REACH programme on industrial chemicals requires that 
existing and new substances should be subject to the same 
toxicity testing procedure under a single system. At pre-
sent, thousands of industrial chemicals are placed on the 
market without proper safety dossiers. As a consequence, 
large amounts of additional tests are required. Addition-
ally, in light of the EU-wide ban on animal use in cosmetics 
development [Council Directive 92/32/EEC (7th Amend-
ment)], there is a need for alternative toxicity tests that are 
not based on animal experimentation. Other EU regula-
tions, e.g. on food chemicals, are directed towards reducing 
animal testing.
In the amendment to the latest consolidated version of 
the REACH legislation, approaches based on toxicogenom-
ics are suggested as alternatives to animal testing. Toxic-
ity testing based on high-throughput ‘omics’ data would 
involve inference of toxicity pathways from large amounts 
of data [National Research Council (NRC) 2007]. In this 
context, several reports provide recommendations on the 
storage and use of big data in toxicogenomics. The NRC 
report “Toxicity Testing in the 21th Century” [National 
Research Council (NRC) 2007] mentions the need for 
central repositories for—omics data. In “A digital agenda 
for Europe” (European Commission 2010a), the European 
commission points out that the scientific community has to 
make use of existing data as much as possible, instead of 
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reproducing data that have already been generated before. 
Against this background, the Blue Ribbon Task Force on 
Sustainable Digital Preservation and Access indicates that 
there is a risk that data get lost and that preservation actions 
need to be taken to assure that data will be available in the 
future (Blue Ribbon Task Force on Sustainable Digital 
Preservation and Access 2010).
The amount of toxicity data is expected to increase in 
the future. Microarray, proteomics, metabolomics and epi-
genomics require several megabytes of storage per experi-
ment. Next-generation sequencing (NGS) will require 
several terabytes of storage per experiment. Furthermore, 
the application of chemoinformatics is expanding, yield-
ing an increasing number of data resources. For instance, 
eChemPortal (http://www.echemportal.org) already cap-
tures more than 25 databases on chemical, physical and 
toxicity information.
Data are driving solutions to complex science and soci-
etal challenges (Beth Plale, Indiana University). Sharing 
and exchange of data will lead to an acceleration of inno-
vation. However, integrating data requires infrastructure 
development, including common metadata standards, an 
integration framework, data access and preservation policy 
and practice, harmonized standards, a common economic 
model for sustaining data, digital object identifiers and 
tools for data discoverability. A number of organizations 
are addressing this need. One of these is the Research 
Data Alliance (RDA) (https://rd-alliance.org/), a global 
community-driven organization launched in March 2013 
to accelerate data-driven innovation. The focus is on build-
ing the infrastructure necessary to enhance data sharing 
and exchange. Furthermore, the RDA aims to accelerate 
the development of a coordinated global data infrastruc-
ture. The RDA operates through its interest and work-
ing groups. RDA interest groups focus on the infrastruc-
ture needed for data sharing and exchange. RDA working 
groups focus on short-term deliverables enhancing data 
sharing and exchange, which can be achieved in a period of 
12–18 months.
The RDA Europe project (https://europe.rd-alliance.
org/), the European plug-in of RDA, focuses on coordi-
nating a series of cross-infrastructure experiments, called 
prototypes, on global interoperability with a selected group 
of projects and communities. Each prototype identifies 
solutions and the remaining challenges for enhancing data 
sharing and exchange in a particular field of research. One 
prototype focuses on global connections between toxicog-
enomics databases and other toxicity data resources, with 
the main focus on connecting EU and US databases. The 
workshop was organized in the framework of RDA Europe, 
in collaboration with NIEHS, in order to discuss available 
EU and US data resources and to identify gaps and needs 
that hamper interoperability.
Toxicogenomics data repositories accepting data 
submissions
Chemical Effects in Biological Systems (CEBS) (Jennifer 
Fostel, NIEHS)
The Chemical Effects in Biological Systems (CEBS) 
(http://cebs.niehs.nih.gov) is a curated, relational, public 
database of data sets from universities, industry and gov-
ernmental institutes developed by the National Toxicology 
Program (NTP). The database houses data from a number 
of different experiment types, including animal studies, 
cellular assays [histopathology, clinical pathology, genetic 
toxicology, immunotoxicology, polymerase chain reaction 
(PCR)] and microarray data. Metadata describe the bio-
logical context, study design, time line, protocols and par-
ticipant characteristics. Conclusions like trial/trend results, 
fold changes and activity calls are also deposited in the 
database. Data from CEBS can be queried and integrated 
across studies. Furthermore, CEBS provides tools for 
visual data mining of all data in a domain (an assay or a 
chemical).
Data are uploaded into the database into a unified for-
mat: the SIFT (Simple Investigation Formatted Text) for-
mat (Waters et al. 2008). The syntax of SIFT is based on 
the SOFT (Simple Omnibus Format in Text) format used 
in the Gene Expression Omnibus (GEO) database (www.
ncbi.nlm.nih.gov/geo/). The SIFT format is used to capture 
study metadata, study data and data transformation. SIFT 
uses Microarray Gene Expression-Tabular (MAGE-TAB) 
for microarray data, a format compliant with the Minimal 
Information About a Microarray Experiment (MIAME). 
Scientists willing to deposit their data into CEBS can cre-
ate a SIFT file incorporating their data and metadata using 
the CEBS DataBuilder, a java tool that can be down-
loaded from the CEBS website. The CEBS data dictionary 
(CEBS-DD) is a compendium of toxicological terms and 
their synonyms used in a variety of toxicological sources. 
Several repositories for toxicogenomics and other toxicity 
data, exchange formats for toxicity data and Lab Informa-
tion Management Systems (LIMS) were studied in order 
to ensure a comprehensive data dictionary that is consist-
ent with other efforts (Fostel et al. 2005). The CEBS data 
dictionary was originally text based, but is now in Extensi-
ble Markup Language (XML) format. Currently, the CEBS 
data dictionary is aligned with Standards for Exchange of 
Nonclinical Data (SEND, http://www.cdisc.org/send) and 
Ontology for Biomedical Investigations (OBI, http://bio-
portal.bioontology.org/ontologies/OBI). When scientists 
deposit data into CEBS, curators verify manually that the 
studies contain biologically sensible information. Further-
more, individuals depositing data into CEBS have to con-
firm that the study is correctly presented. When importing 
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data from other sources, automated scripts are used to 
check whether the studies are imported correctly. CEBS 
works with pathologists and ontologists on the consolida-
tion of ontology terms. Currently, CEBS is working on a 
project toward linked data (structured and computer-reada-
ble data that can be interlinked).
The diXa data infrastructure (Ugis Sarkans, EBML-EBI)
The diXa infrastructure (http://www.dixa-fp7.eu/) consists 
of a central data warehouse containing data from toxicog-
enomics project repositories and public databases. Apart 
from data from European projects, diXa also includes the 
public data from the National Project of Toxicogenomics in 
Japan, named Open TG-GATES (Toxicogenomics Project-
Genomics Assisted Evaluation System, see below for more 
details).
The diXa data warehouse connects multi-omics studies, 
deposited in EBI resources [ArrayExpress for transcrip-
tomics (http://www.ebi.ac.uk/arrayexpress/), PRIDE for 
proteomics (http://www.ebi.ac.uk/pride/archive/), Metabo-
Lights for metabolomics (http://www.ebi.ac.uk/metabo-
lights/)] and provides a single interface for search and 
retrieval of “omics” data. In this way, data can be reused in 
cross-platform projects.
The diXa data warehouse is connected to a chemicals 
database portal and a human diseases database portal. Data 
from external sources are integrated in the chemicals data-
base portal via InChI/Keys (textual identifiers for chemical 
substances). The chemicals database portal provides cross-
links to other databases with chemicals and their activities. 
In the human diseases database portal, molecular data on 
human diseases are retrieved from public data sources.
All data submitted to the diXa warehouse are subjected 
to quality control using Genedata Expressionist® (https://
www.genedata.com/products/expressionist/) quality con-
trol pipelines. When a data set is submitted to diXa, the 
diXa staff checks whether the data and metadata are in an 
acceptable format. They also examine whether the meta-
data are complete and that the data can correctly be read 
in the specified format. Furthermore, the diXa staff dou-
ble-checks with submitters that the information accurately 
reflects the experimental procedures performed. Moreover, 
the data have to pass a minimum of quality control pro-
cedures. Finally, requirements that have to be fulfilled so 
that data can be properly analysed (e.g. control samples for 
comparisons, enough samples) are checked.
Data and metadata have to be uploaded in ISA-TAB for-
mat (Rocca-Serra et al. 2010). The ISA-TAB format pro-
vides fields for the metadata and links to the external files 
containing the data.
To keep researchers up to date on the development of 
the diXa infrastructure, training courses and workshops 
are organized on a regular basis at different locations in 
Europe. Stakeholders are engaged in the diXa project by 
conducting a survey of other EU toxicogenomics projects, 
in order to understand data and user expectations and to 
build trust.
Toxicogenomics databases primarily intended 
as information resources
Comparative Toxicogenomics Database (CTD) (Caroline 
Mattingly, North Carolina State University)
Currently, more than 60,000 toxic substances are on 
the market, and ~2,000 substances are added each year. 
Approximately 8,000 chemicals are carcinogens. For 
~40 % of the 3,300 chemicals that are produced in high 
amounts, no toxicity data are available. Moreover, full tox-
icity data are available for only 25 % of the chemicals that 
are found in consumer products. This hampers obtaining 
insight in how chemicals affect our health. The Compara-
tive Toxicogenomics Database (CTD) (http://ctdbase.org/) 
is a manually curated repository of chemicals, genes, dis-
eases and their interactions from the curated scientific lit-
erature, which has the aim to improve the understanding of 
the adverse effects of chemicals on our health. CTD pro-
vides tools for visualizing the interactions and to perform 
enrichment analysis on a set of genes or chemicals.
CTD includes over 12,000 chemicals, over 30,000 genes 
and over 6,000 diseases. Furthermore, CTD contains more 
than 860,000 curated chemical–gene interactions, more 
than 27,000 curated gene–disease relationships and more 
than 180,000 curated chemical–disease relationships. Over 
300 manuscripts use CTD data, and more than 30 public 
databases incorporate CTD data.
CTD uses several ontologies, including EntrezGeneID, 
Medical Subject Headings (MeSH; Davis et al. 2009) and 
CTD’s merged disease vocabulary (MEDIC; Davis et al. 
2012). Gene ontology (GO) and pathways from KEGG 
(Kyoto Encyclopedia of Genes and Genomes) and Reac-
tome are integrated into CTD (Davis et al. 2013). CTD is 
also developing exposure ontology (ExO) and will inte-
grate exposure and phenotypic data with the other informa-
tion in the database in order to infer relationships between 
chemicals, phenotypes and diseases (Mattingly et al. 2012).
Library of Integrated Network Based Cellular Signatures 
(LINCS) (Aravind Subramanian, Broad Institute)
The Library of Integrated Network Based Cellular Sig-
natures (LINCS) (http://www.lincsproject.org/) aims 
to serve as a source for improving the understanding 
of cellular activity and is based on Connectivity Map 
(CMap). CMap (https://www.broadinstitute.org/cmap/) is 
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a database that uses mRNA expression signatures from 
cultured human cells treated with bioactive small mole-
cules to connect diseases, genes and drugs. The database 
includes 453 Affymetrix profiles for 164 drugs. CMap 
has more than 16,000 users and is cited in more than 900 
publications (Lamb et al. 2006). LINCS expands CMap 
by including more small molecules, genomic perturba-
tions, cellular contexts and treatment parameters. The 
representation of the human transcriptome is reduced tak-
ing advantage of correlation in gene expression. A set of 
1,000 landmark genes is selected that captures approxi-
mately 80 % of the correlations in gene expression pro-
files. The complete list of landmark genes is available 
on http://www.lincscloud.org/l1000/. Currently, LINCS 
contains expression profiles for 5,178 compounds and 
15 cell types for the 1,000 landmark genes and 21,000 
inferred genes. Furthermore, LINCS contains data from 
gene knockdown experiments (3,712 genes). Data quality 
is checked by calculating Spearman correlation between 
biological replicate signatures.
Toxicogenomics Genomics-Assisted Toxicity Evaluation 
system: Open TG-GATEs (Florian Caiment, Maastricht 
University)
Open TG-GATEs (http://toxico.nibio.go.jp/english/index.
html) is a public database consisting of in vivo (rat) and 
in vitro (human and rat) clinical, pathological and expres-
sion data for approximately 170 toxic compounds from the 
National Projects of Toxicogenomics in Japan, generated 
from liver and kidney. The database contains more than 
20,000 Affymetrix microarray profiles. The experimental 
design is the same for each compound. In vivo (liver and 
kidney) data consist of three biological replicates, meas-
ured at eight time points and four dose levels. The in vitro 
(rat and human hepatocyte) data consist of two biological 
replicates, measured at three time points and four dose lev-
els. Microarray profiles are stored as CEL files. Clinical 
data are displayed as tables, and pathological data as both 
images and tables.
Data quality is checked by evaluating inter- and intra-
laboratory reproducibility of biological replicates by 
clustering, Spearman correlation and determining the 
overlap in lists of differentially expressed genes (Nori-
yuki et al. 2012). Further quality control is performed 
using the ArrayAnalysis Quality Control pipeline (www.
arrayanalysis.org/). Toxygates (http://toxygates.nibio.
go.jp/toxygates/) is a platform for analysing the TG-
GATEs data (Nystrom-Persson et al. 2013). Given a list 
of genes or probes, the following tools can be used to 
analyse the data: KEGG pathway analysis, GO analysis, 
analysis of ChEMBL or DrugBank targets and compound 
ranking.
DrugMatrix (Scott Auerbach, NIEHS)
DrugMatrix (https://ntp.niehs.nih.gov/drugmatrix/index.
html) is a public, comprehensive, database of gene expres-
sion profiles, pathology assays and pharmacology assays 
hosted as a resource to researchers by the National Toxi-
cology Program (NTP). DrugMatrix contains data from 
expression studies for over 600 compounds, including 
~4,000 dose time–tissue combinations, ~2 million dosed 
tissue samples, ~18,000 microarrays, ~127,000 histopathol-
ogy measurements and ~100,000 haematology and chemis-
try measurements. Furthermore, more than 800 compounds 
were profiled across 130 in vitro pharmacology assays. The 
database also provides links to the drug literature (Fielden 
and Halbert 2007). Currently, the TG-GATEs data are 
added to DrugMatrix. All data in DrugMatrix are gener-
ated through a standardized experimental protocol utiliz-
ing rats or primary rat hepatocytes systematically treated 
with therapeutic, environmental and industrial chemicals at 
both toxic and non-toxic doses (Ganter et al. 2006). Unpro-
cessed and normalized Affymetrix microarray data can be 
downloaded from the FTP site (ftp://anonftp.niehs.nih.gov/
drugmatrix). DrugMatrix contains hundreds of drug signa-
tures (biomarkers) for liver, heart, kidney, muscle and pri-
mary hepatocytes. The DrugMatrix Toolbox and ToxFX 
provide tools for data analysis (Fielden and Halbert 2007).
The DrugMatrix Toolbox allows users to upload their 
data or mine the DrugMatrix data. The following data anal-
ysis tools are available: finding similar expression profiles, 
hierarchical clustering, finding consistently changed genes, 
differentially expressed genes (DEGs) analysis, pathway 
analysis and gene ontology (GO) analysis. Furthermore, 
expression profiles can be visualized on pathways. Expres-
sion profiles for more than 50 phenotypes can be scored 
with drug signatures. Expression patterns for putative 
biomarker sets can be constructed, and the performance 
of biomarker sets for detecting phenotypes can be tested. 
Moreover, the DrugMatrix Toolbox provides tools to mine 
the literature and to identify enriched literature annotations 
in groups of expression profiles.
ToxFX (https://ntp.niehs.nih.gov/toxfx/) is a rapid, auto-
mated toxicogenomics analysis tool including quality con-
trol, scoring of expression profiles with drug signatures, 
DEGs analysis and pathway analysis. ToxFX generates a 
detailed toxicogenomics report in five minutes.
Chemoinformatics databases
ChEMBL (Anne Hersey, EMBL-EBI)
ChEMBL (https://www.ebi.ac.uk/chembl/) is an open-
access database of bioactivity data for drug discovery 
maintained by the European Bioinformatics Institute (EBI). 
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The database, originally developed by a biotechnology 
company, consists of data manually extracted from the lit-
erature, a subset of data from PubChem (https://pubchem.
ncbi.nlm.nih.gov/) and deposited data. Bioactivity data are 
associated with a biological target and a chemical structure. 
Compounds are stored in a structure-searchable format. 
Protein targets are linked to protein sequences in UniProt 
(http://www.uniprot.org/). ChEMBL is updated regularly 
with new data. ChEMBL covers about 1,300,000 drug-
like molecules, over 10,000,000 activities, over 700,000 
assays, about 10,000 targets and links to more than 50,000 
documents.
For each compound, compound details, assay details, 
target details and literature references are provided 
(Gaulton et al. 2012). Several types of targets are included 
in ChEMBL: proteins, protein complexes, protein fami-
lies, nucleic acids, cell lines, tissues, sub-cellular fractions 
and organisms. ChEMBL contains binding, functional and 
ADMET (Absorption, Distribution, Metabolism, Excretion 
and Toxicity) assays.
ChEMBL data can be accessed by downloads or web 
services that allow to search by compound or target. 
ChEMBL provides links to other public resources, e.g. 
compound and protein databases (Warr 2009). Additionally, 
ChEMBL provides tools and resources for data mining.
Currently, ChEMBL is working on importing data from 
DailyMed (http://dailymed.nlm.nih.gov/dailymed/about.
cfm), a database with medication information.
Unified Chemical Identifier System (UniChem) (Anne 
Hersey, EMBL-EBI)
Multiple resources hold compound data, and maintaining 
the links between all these databases is time-consuming. 
Furthermore, rules for constructing identifiers are not con-
sistent among databases.
UniChem (Unified Chemical Identifier system) tries 
to cope with these problems by providing important links 
between databases that contain compound structures 
[e.g. DrugBank (http://www.drugbank.ca/), ChEMBL]. 
InChiKeys are used as a unified chemical identifier. 
UniChem contains data from 16 sources on more than 
31,000,000 structures. UniChem provides web services for 
identifier searching or source mapping between databases 
(Chambers et al. 2013).
Microarray and Sequencing Quality Control (Weida Tong, 
FDA)
The US Food and Drug Administration’s (FDA) Micro-
Array Quality Control project (MAQC) (http://www.
fda.gov/ScienceResearch/BioinformaticsTools/Microar-
rayQualityControlProject/) focuses on microarrays and 
next-generation sequencing technology in three phases. 
MAQC I assesses the reliability, repeatability and repro-
ducibility of microarray data (Shi et al. 2006). A total of 
137 participants from 51 organizations were involved. 
MAQC II studies the reliability of microarray-based bio-
markers in clinical studies and toxicology (Shi et al. 2010). 
A total of 202 participants from 97 organizations were 
involved. MAQC III, also called Sequencing Quality Con-
trol (SEQC), assesses the reliability of next-generation 
sequencing (NGS) experiments and compares them with 
microarrays (Wang et al. 2014). A total of 180 participants 
from 73 organizations were involved. During the SEQC 
study, over 10 terabytes of more than 100 billion reads 
were generated.
Cross-site and cross-platform reproducibility of NGS 
data were compared to microarrays and quantitative poly-
merase chain reaction (qPCR). NGS data were more simi-
lar to qPCR data than microarrays. Moreover, the iden-
tification of differentially expressed genes (DEGs) was 
compared between NGS and microarrays. When the treat-
ment response was strong, NGS detected more DEGs than 
microarrays. When the treatment response was weak, Affy-
metrix microarrays detected more DEGs than NGS. Fur-
ther, the strength of the treatment response determined the 
degree of overlap between microarrays and NGS.
Furthermore, samples were randomly split into a train-
ing set and a test set with approximately the same size. 
Classifiers were developed with the training set, and the 
reliability of these classifiers was examined with the test 
set. Performance of the classifiers was compared between 
NGS and microarray data. No significant differences were 
found between the two platforms.
Finally, 278 pipelines for analysing NGS data were 
evaluated in order to make a pipeline selection guide for 
decision-making.
MAQC and SEQC datasets are publicly available from 
the MAQC website or from another public data resource 
(GEO, ArrayTrack or CEBS; Shi et al. 2006, 2010).
WikiLIMS: A Laboratory Information Management 
System for Toxicogenomics (Stephen Edwards, EPA)
An adverse outcome pathway (AOP) is a series of key 
events describing how exposure to an environmental 
stressor leads to an adverse outcome. At the systems biol-
ogy level, three types of networks are involved in an AOP: 
the molecular network, the key event network and the pop-
ulation network (Edwards and Preston 2008). To enable 
systems’ biology approaches, data management systems 
need to be capable of handling large amounts of heteroge-
neous data.
WikiLIMS (http://bioteam.net/tag/wikilims/) is a Lab-
oratory Information Management System (LIMS) for 
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toxicogenomics, developed at the United States Environ-
mental Protection Agency (EPA). The goal of WikiLIMS 
is to enhance human health risk assessment through data 
integration within EPA. WikiLIMS is a non-public system 
that can handle many different data types and is easy to 
update when more data become available. WikiLIMS cur-
rently only handles non-public data within the Office of 
Research and Development (ORD) at the EPA. WikiLIMS 
provides links to US EPA public databases (ACToR, DSS-
Tox, ExpoCastDB, ToxCastDB and ToxRefDB, see http://
actor.epa.gov/).
Proof of principle of meta-analysis in toxicogenomics 
(Florian Caiment, Maastricht University)
To demonstrate the strength of combining data from differ-
ent resources for improving toxicological risk assessment 
in humans, within the diXa project, a follow-up work on the 
integration of human disease data with molecular toxico-
logical data derived from human in vitro models was con-
ducted. The research focused on hepatocellular carcinoma 
(HCC), which is the fifth most common cancer worldwide 
and the third most common cause of cancer mortality. HCC 
accounts for approximately 90 % of primary liver cancers 
and is induced either by hepatic viral infections or hepatic 
cirrhosis.
Connectivity Map, data from Open TG-GATEs and pub-
licly available data on liver carcinogens [from the Interna-
tional Agency for Research on Cancer (http://www.iarc.
fr/), the US EPA, the NTP and the Carcinogenic Potency 
Project (http://toxnet.nlm.nih.gov/cpdb/)] were integrated 
with data derived from human HCC (among others from 
ArrayExpress) to allow better classification of carcinogenic 
compounds. The results demonstrated that combining data 
from different sources increased the accuracy of liver carci-
nogenicity predictions (Caiment et al. 2014).
General discussion
Data sharing and exchange in toxicogenomics: gaps 
and needs
The general discussion after the presentations focused 
mainly on non-confidential data that can be made publicly 
available without coping with privacy issues. Four types of 
problems hampering data sharing and exchange in toxicog-
enomics were discussed: communication problems, prob-
lems related to the quality of the data, sustainability prob-
lems and need for training and support.
Communication problems occur between partners of dif-
ferent disciplines. Researchers involved in toxicogenomics 
projects are often from different disciplines, including toxi-
cologists, data managers and technological persons. Each 
discipline developed terminologies, reporting guidelines, 
data formats and metadata formats that are in agreement 
with a specific set of needs. As a consequence, it is diffi-
cult to define standards in the field of toxicogenomics. The 
best-case scenario would be that scientists from differ-
ent disciplines define consensus terminologies, standards 
and formats for toxicogenomics. If it appears not possible 
to reach consensus, an alternative may be to make exist-
ing terminologies, standards and formats interoperable. 
This can be accomplished by establishing dictionaries with 
synonyms (e.g. the CEBS data dictionary) and/or mapping 
between standards.
Reuse of public data in new projects requires that the 
users have to be certain that the data are of good quality. 
Problems related to data quality can consist of mistakes in 
the data and metadata, insufficient metadata and poor qual-
ity of the data themselves (in terms of reliability, repro-
ducibility and repeatability). Therefore, data deposited in 
public repositories have to be subjected to thorough quality 
control before making it public. Several public databases 
already fulfil this requirement, but quality control work-
flows are not harmonized across different data repositories 
containing data from the same measurement technology. 
An evaluation of quality control pipelines for each plat-
form, like the one conducted for NGS data in the SEQC 
study, can guide harmonization of quality control by identi-
fying best practices.
Data infrastructures have to be sustainable, taking into 
account the evolution of the field. Because data infrastruc-
tures and services are not often cited, their impact is under-
estimated by funding agencies. This leads to problems 
regarding the funding for extending the databases accord-
ing to new developments in the field, as well as mainte-
nance of existing resources. The participants of the work-
shop recommend defining a persistent identifier for the use 
of data infrastructures. A persistent identifier would enable 
better citations of the infrastructures, which hopefully 
would have a positive effect on available funding. Further-
more, in this way, the number of studies per year using a 
particular database, and thus a measure of impact, can be 
better reflected by mining the literature.
Generally, data infrastructures have been insufficiently 
supported. Beyond the infrastructure itself, people involved 
in using, developing and maintaining data infrastructures, 
need appropriate training and support. This includes help 
with implementation, offering courses on e-infrastructures 
and organizing forums to ask questions and discuss topics.
Table 1 summarizes how the different databases, studies, 
organizations and tools presented at this workshop attempt 
to deal with the problems outlined above.
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Generating a roadmap to enhance interoperability 
of existing data infrastructures
With a number of issues brought forth during the course of 
the workshop, any roadmap towards improvement would 
be a first step. There was agreement that the roadmap 
should include the structure of the RDA to further advance 
a number of key issues.
The case study presented at the workshop showed that 
combining data from different sources increased the accu-
racy of predictions in risk assessment. Some of the data 
resources presented at the workshop are already linked (see 
Fig. 1). The workshop participants agreed that providing 
more links between the different resources will facilitate 
toxicogenomics research.
Table 1  Summary of the databases, studies, organizations and tools presented at the workshop and how they deal with problems regarding com-




Communication Quality Sustainability Training and support
RDA X X Working and interest groups
Forum
CEBS X X X Unified format (SIFT)
CEBS data dictionary
Curation of data
Possibility to deposit new data
diXa X X X X InChI/Keys for chemicals
Unified format for metadata (ISA-TAB)
Quality control pipeline (Genedata)
Possibility to deposit new data
Training and workshops
CTD X X X Use of ontologies




LINCS X Reproducibility between replicates checked
TG-GATEs X X Same experimental design for all experi-
ments
Data checked on reproducibility between 
replicates
DrugMatrix & ToxFX X X Standardized experimental protocol
ToxFX provides tools for quality control
ChEMBL X X Data in a unified format
Regularly updated
UniChem X Unified chemical identifier
MAQC & SEQC X X Data deposited in public resources that used 
standardized formats, e.g. CEBS
Assess reliability, repeatability and repro-
ducibility of microarrays and NGS data
Comparing different quality control pipe-
lines currently in use for NGS data
WikiLIMS X Can handle many different data types/
formats
Easy to update
Fig. 1  Links between the different data sources presented at the 
workshops. Dashed lines indicate ongoing efforts
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Across the existing landscape, resources need to be 
made easier to find. The workshop participants agreed 
that there is a need for a web portal that provides links to 
all databases relevant for toxicogenomics and that gives a 
description of the information and experimental data that 
are deposited in each database.
When considering an approach to these issues, it became 
obvious that any roadmap must be grounded in the needs of 
potential users. User stories highlighting research currently 
limited due to a lack of interoperability of data resources 
would need to be collected. By analysing user stories, more 
use cases can be defined that are limited by the current sci-
entific gaps due to the lack of data exchange. These use 
cases can be utilized to support the prioritization of steps 
that need to be undertaken for linking data resources.
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